(Q35737411)

10 August 2017

1 reference

title

Biologic therapy of liver tumors (English)

1 reference

10 August 2017

author

Ignacio Melero, MD-PhD

4

object named as

Ignacio Melero

1 reference

10 August 2017

Jesus Prieto

1

1 reference

10 August 2017

Cheng Qian

2

1 reference

10 August 2017

Bruno Sangro

3

1 reference

10 August 2017

Guillermo Mazzolini

5

1 reference

10 August 2017

publication date

1 April 2004

1 reference

Surgical Clinics of North America

10 August 2017

published in

1 reference

10 August 2017

volume

84

1 reference

10 August 2017

issue

2

1 reference

10 August 2017

page(s)

673-696

1 reference

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Phase II study of megestrol acetate in the treatment of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Regulatory peptide receptors in human hepatocellular carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

The epidermal growth factor receptor and its inhibition in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Epidermal growth factor receptor-targeted therapy in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Retinoic acid metabolism and mechanism of action: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Retinoids in cancer prevention and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Phase II trial of oral beta-all trans-retinoic acid in hepatocellular carcinoma (SWOG 9157).

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Multi-modality treatment of primary nonresectable intrahepatic cholangiocarcinoma with 131I anti-CEA--a Radiation Therapy Oncology Group Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Clinical translation of angiogenesis inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Angiogenesis in cancer, vascular, rheumatoid and other disease

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Molecular Imaging and Biological Evaluation of HuMV833 Anti-VEGF Antibody: Implications for Trial Design of Antiangiogenic Antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

A phase II study of mitoxantrone combined with beta-interferon in unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Recombinant human gamma-interferon in primary hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Recombinant interferon-α in inoperable hepatocellular carcinoma: A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Phase II study of fluorouracil, leucovorin, and interferon alfa-2a in metastatic colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Biochemical modulation of 5-fluorouracil by leucovorin with or without interferon-alpha-2c in patients with advanced colorectal cancer: final results of a randomised phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Fluorouracil and leucovorin with or without interferon alfa-2a as adjuvant treatment, in patients with high-risk colon cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Ultra-low-dose interleukin-2 in unresectable hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Low-dose interleukin-2 subcutaneous immunotherapy in association with the pineal hormone melatonin as a first-line therapy in locally advanced or metastatic hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Immunotherapy of hepatocellular carcinoma with autologous lymphokine-activated killer cells and/or recombinant interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates the size, reactivity, and function of a primed pool of CD4+ T cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

CD40 ligation for immunotherapy of solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Therapeutic vaccination for cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Dendritic cell-based vaccination in solid cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Induction of Tumor-Specific Cytotoxic T Lymphocytes in Cancer Patients by Autologous Tumor RNA-Transfected Dendritic Cells

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

The basic science of gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Human gene therapy comes of age.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Viruses as gene delivery vectors: application to gene function, target validation, and assay development

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Non-viral gene delivery systems

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Gene therapy of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Angiostatin induces and sustains dormancy of human primary tumors in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

A novel strategy for the generation of angiostatic kringle regions from a precursor derived from plasminogen.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

A "distant" bystander effect of suicide gene therapy: regression of nontransduced tumors together with a distant transduced tumor

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Combined gene therapy with suicide gene and interleukin-12 is more efficient than therapy with one gene alone in a murine model of hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Transduction efficacy, antitumoral effect, and toxicity of adenovirus-mediated herpes simplex virus thymidine kinase/ ganciclovir therapy of hepatocellular carcinoma: the woodchuck animal model

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Gene transfer and therapy with adenoviral vector in rats with diethylnitrosamine-induced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Severe hepatic dysfunction after adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene and ganciclovir administration.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Tumor-specific transcriptional targeting of suicide gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Regional delivery of an adenovirus vector containing the Escherichia coli cytosine deaminase gene to provide local activation of 5-fluorocytosine to suppress the growth of colon carcinoma metastatic to liver.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

In VivoAdenovirus-Mediated Gene Transfer of theEscherichia coliCytosine Deaminase Gene to Human Colon Carcinoma-Derived Tumors Induces Chemosensitivity to 5-Fluorocytosine

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Interleukin-12: a cytokine at the interface of inflammation and immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Adenoviral gene transfer of interleukin 12 into tumors synergizes with adoptive T cell therapy both at the induction and effector level

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Alpha(v)beta(3) integrin-mediated adenoviral transfer of interleukin-12 at the periphery of hepatic colon cancer metastases induces VCAM-1 expression and T-cell recruitment

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Genetic heterogeneity in the toxicity to systemic adenoviral gene transfer of interleukin-12.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Pancreatic cancer escape variants that evade immunogene therapy through loss of sensitivity to IFNgamma-induced apoptosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Mouse alpha-fetoprotein-specific DNA-based immunotherapy of hepatocellular carcinoma leads to tumor regression in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Prime boost vaccination strategies: CD8 T cell numbers, protection, and Th1 bias

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Intratumoral adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: results of a phase I clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Tracing transgene expression in cancer gene therapy: a requirement for rational progress in the field.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

A blood-tumor barrier limits gene transfer to experimental liver cancer: the effect of vasoactive compounds.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

BIOLOGY OF HEMATOPOIETIC STEM CELLS AND PROGENITORS: Implications for Clinical Application

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Mesenchymal stem cells: biology and potential clinical uses

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Origin of endothelial progenitors in human postnatal bone marrow

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

RETRACTED: Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

Putting the neo into neoangiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900230-5

7 January 2021

10.1016/S0039-6109(03)00230-5

Identifiers

DOI

1 reference

10 August 2017

1 reference